fluoxetine and selegiline

fluoxetine has been researched along with selegiline in 40 studies

Research

Studies (40)

TimeframeStudies, this research(%)All Research%
pre-19902 (5.00)18.7374
1990's14 (35.00)18.2507
2000's17 (42.50)29.6817
2010's7 (17.50)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Topliss, JG; Yoshida, F1
Adkison, KK; Humphreys, JE; Mahar Doan, KM; Polli, JW; Serabjit-Singh, CJ; Shampine, LJ; Webster, LO; Wring, SA1
Dansette, PM; Fontana, E; Poli, SM1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Bergström, F; Giordanetto, F; Rehngren, M; Tunek, A; Wan, H1
Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J1
Bolognesi, ML; Cavalli, A; Melchiorre, C; Minarini, A; Recanatini, M; Rosini, M; Tumiatti, V1
Ahman, M; Holmén, AG; Wan, H1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Frazer, A; Mendels, J; Savage, DD1
Follender, AB; Hughes, PL; Jermain, DM1
Hawkins, JW1
deVries, J; Suchowersky, O1
deVries, JD; Suchowersky, O1
Buckholtz, NS; Sparks, DL1
Garcia-Monco, JC; Gomez Beldarrain, M; Padierna, A1
Waters, CH1
Chamontin, B; Llau, ME; Montastruc, JL; Rascol, A; Rascol, O; Senard, JM; Tran, MA1
Azmitia, EC; Gu, XF1
Iacono, RP; Toyama, SC1
Andrews, AM; Murphy, DL1
Adler, L; Huether, G; Poeggeler, B; Rüther, E1
Asnis, J; Patel, SV; Tariot, PN1
Klenk-Majewska, B; Lupina, T; Ossowska, G; Pietrasiewicz, T; Zebrowska-Lupina, I1
Oakley, F; Sunderland, T1
Marsh, C; Preskorn, SH; Shad, MU1
Bilbao Garay, J; Castilla Castellano, V; Dhimes Tejada, P; Mesa Plaza, N1
Brown, AW; Hrometz, SL; Nichols, DE; Sprague, JE1
Carey, GJ; Gold, LH; Nielsen, DM1
Csoka, AB; Shipko, S1
Cano, E; Fraiz, N; Orallo, F; Yáñez, M1
Blaugrund, E; Cohen, S; Eliash, S; Fine, T; Litinetsky, L; Speiser, Z1
Preskorn, SH1
Borowsky, R; Hoekstra, HE; Jeffery, WR; Kay, EH; Kowalko, JE; Linden, TA; Peterson, BK; Rohner, N; Rompani, SB; Tabin, CJ; Weber, J; Yoshizawa, M1
Fink-Gremmels, J; Schrickx, JA1
Forsblad, A; Hashemian, S; Jacobsson, SO; Popova, D1
Chamanara, M; Dehpour, AR; Nikoui, V; Norouzi-Javidan, A; Ostadhadi, S; Shakiba, S; Zolfaghari, S1

Reviews

4 review(s) available for fluoxetine and selegiline

ArticleYear
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
    Current drug metabolism, 2005, Volume: 6, Issue:5

    Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Structure-Activity Relationship; Terminology as Topic

2005
Multi-target-directed ligands to combat neurodegenerative diseases.
    Journal of medicinal chemistry, 2008, Feb-14, Volume: 51, Issue:3

    Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Binding Sites; Calcium Channel Blockers; Chelating Agents; Cholinesterase Inhibitors; Humans; Huntington Disease; Ligands; Multiple Sclerosis; Neurodegenerative Diseases; Neurofibrillary Tangles; Neurotransmitter Agents; Parkinson Disease; Plaque, Amyloid

2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
[Serotonin syndrome: report of a fatal case and review of the literature].
    Revista clinica espanola, 2002, Volume: 202, Issue:4

    Topics: Aged; Antiparkinson Agents; Carbidopa; Depressive Disorder, Major; Drug Combinations; Drug Synergism; Fatal Outcome; Fluoxetine; Humans; Levodopa; Male; Parkinson Disease; Selective Serotonin Reuptake Inhibitors; Selegiline; Serotonin Syndrome

2002

Trials

2 trial(s) available for fluoxetine and selegiline

ArticleYear
Fluoxetine and selegiline--lack of significant interaction.
    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1994, Volume: 21, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Depressive Disorder; Drug Interactions; Female; Fluoxetine; Humans; Male; Middle Aged; Parkinson Disease; Selegiline

1994
Assessment of motor and process skills as a measure of IADL functioning in pharmacologic studies of people with Alzheimer's disease: a pilot study.
    International psychogeriatrics, 1997, Volume: 9, Issue:2

    Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Motor Skills; Neuropsychological Tests; Nootropic Agents; Physostigmine; Pilot Projects; Problem Solving; Psychometrics; Reproducibility of Results; Selegiline; Treatment Outcome

1997

Other Studies

34 other study(ies) available for fluoxetine and selegiline

ArticleYear
QSAR model for drug human oral bioavailability.
    Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13

    Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship

2000
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
    The Journal of pharmacology and experimental therapeutics, 2002, Volume: 303, Issue:3

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Cell Line; Cell Membrane Permeability; Central Nervous System Agents; Dogs; Drug Delivery Systems; Permeability; Pharmaceutical Preparations

2002
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
    Journal of medicinal chemistry, 2007, Sep-20, Volume: 50, Issue:19

    Topics: Animals; Brain; Central Nervous System Agents; Dialysis; Hydrophobic and Hydrophilic Interactions; In Vitro Techniques; Mice; Models, Statistical; Protein Binding; Quantitative Structure-Activity Relationship; Rats

2007
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
    Journal of medicinal chemistry, 2008, Jan-24, Volume: 51, Issue:2

    Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase

2008
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
    Journal of medicinal chemistry, 2009, Mar-26, Volume: 52, Issue:6

    Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry

2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
    Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3

    Topics:

2008
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10

    Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding

2012
Differential effects of monoamine oxidase inhibitors and serotonin reuptake inhibitors on 3H-serotonin receptor binding in rat brain.
    European journal of pharmacology, 1979, Sep-01, Volume: 58, Issue:1

    Topics: Animals; Brain; Clomipramine; Clorgyline; Fluoxetine; Male; Monoamine Oxidase Inhibitors; Rats; Receptors, Serotonin; Selegiline; Serotonin Antagonists

1979
Potential fluoxetine-selegiline interaction.
    The Annals of pharmacotherapy, 1992, Volume: 26, Issue:10

    Topics: Aged; Ataxia; Depression; Drug Interactions; Female; Fluoxetine; Humans; Parkinson Disease; Selegiline

1992
Nonsedating treatments for Alzheimer's patients with behavioral problems.
    The Journal of clinical psychiatry, 1992, Volume: 53, Issue:3

    Topics: Alzheimer Disease; Buspirone; Fluoxetine; Humans; Selegiline; Sleep; Trazodone

1992
Possible interactions between deprenyl and prozac.
    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1990, Volume: 17, Issue:3

    Topics: Drug Interactions; Female; Fluoxetine; Humans; Middle Aged; Parkinson Disease; Selegiline

1990
Interaction of fluoxetine and selegiline.
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 1990, Volume: 35, Issue:6

    Topics: Bipolar Disorder; Depressive Disorder; Drug Synergism; Drug Therapy, Combination; Female; Fluoxetine; Humans; Hypertension; Middle Aged; Selegiline

1990
Effects of 6-methoxy-1,2,3,4-tetrahydro-beta-carboline (6-MeO-THbetaC) on audiogenic seizures in DBA/2J mice.
    Pharmacology, biochemistry, and behavior, 1980, Volume: 12, Issue:1

    Topics: 5-Hydroxytryptophan; Acoustic Stimulation; Animals; Benzofurans; Carbolines; Citalopram; Clomipramine; Clorgyline; Fluoxetine; Harmine; Indoles; Methoxydimethyltryptamines; Mice; Mice, Inbred DBA; N,N-Dimethyltryptamine; Pargyline; Propylamines; Quipazine; Seizures; Selegiline

1980
Selegiline, fluoxetine, and depression in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 1995, Volume: 10, Issue:3

    Topics: Aged; Depressive Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoxetine; Humans; Parkinson Disease; Selegiline

1995
Pseudophaeochromocytoma in parkinsonian patient treated with fluoxetine plus selegiline.
    Lancet (London, England), 1993, Feb-27, Volume: 341, Issue:8844

    Topics: Adrenal Gland Neoplasms; Adult; Catecholamines; Diagnosis, Differential; Drug Interactions; Female; Fluoxetine; Humans; Hypertension; Parkinson Disease; Pheochromocytoma; Selegiline

1993
Integrative transporter-mediated release from cytoplasmic and vesicular 5-hydroxytryptamine stores in cultured neurons.
    European journal of pharmacology, 1993, Apr-22, Volume: 235, Issue:1

    Topics: 3,4-Methylenedioxyamphetamine; Animals; Brain Stem; Carrier Proteins; Cells, Cultured; Clorgyline; Female; Fluoxetine; Membrane Glycoproteins; Membrane Transport Proteins; N-Methyl-3,4-methylenedioxyamphetamine; Nerve Tissue Proteins; Neurons; Nimodipine; p-Chloroamphetamine; Pregnancy; Rats; Rats, Sprague-Dawley; Reserpine; Selegiline; Serotonin; Serotonin Plasma Membrane Transport Proteins

1993
Is it safe to combine a selective serotonin reuptake inhibitor with selegiline?
    The Annals of pharmacotherapy, 1994, Volume: 28, Issue:3

    Topics: 1-Naphthylamine; Drug Interactions; Drug Therapy, Combination; Fluoxetine; Humans; Parkinson Disease; Paroxetine; Selective Serotonin Reuptake Inhibitors; Selegiline; Sertraline

1994
2'-NH2-MPTP in Swiss Webster mice: evidence for long-term (6-month) depletions in cortical and hippocampal serotonin and norepinephrine, differential protection by selective uptake inhibitors or clorgyline and functional changes in central serotonin neuro
    The Journal of pharmacology and experimental therapeutics, 1993, Volume: 267, Issue:3

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cerebral Cortex; Clorgyline; Desipramine; Fluoxetine; Hippocampus; Male; Mice; Monoamine Oxidase Inhibitors; MPTP Poisoning; Neurotransmitter Uptake Inhibitors; Norepinephrine; Paroxetine; Selegiline; Serotonin; Serotonin Receptor Agonists; Synaptic Transmission; Time Factors

1993
Effects of indirectly acting 5-HT receptor agonists on circulating melatonin levels in rats.
    European journal of pharmacology, 1993, Jul-20, Volume: 238, Issue:2-3

    Topics: 3,4-Methylenedioxyamphetamine; Animals; Fenfluramine; Fluoxetine; Injections, Intraperitoneal; Male; Melatonin; Pargyline; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Selegiline; Serotonin Receptor Agonists; Tryptophan

1993
L-Deprenyl augmentation of fluoxetine in a patient with Huntington's disease.
    Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 1996, Volume: 8, Issue:1

    Topics: Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Attention; Carbamazepine; Depression; Drug Interactions; Drug Therapy, Combination; Expressed Emotion; Female; Fluoxetine; Humans; Huntington Disease; Impulsive Behavior; Monoamine Oxidase Inhibitors; Movement; Selegiline; Violence

1996
ACTH 4-9 analogue facilitates the antiimmobility effect of antidepressants and dopamine agonists in swimming rats.
    Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 1997, Volume: 48, Issue:2

    Topics: Adrenocorticotropic Hormone; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Dopamine Agonists; Exploratory Behavior; Fear; Fluoxetine; Fluvoxamine; Monoamine Oxidase Inhibitors; Motor Activity; Peptide Fragments; Piribedil; Quinpirole; Rats; Rats, Wistar; Selegiline; Swimming

1997
The economic consequences of a drug-drug interaction.
    Journal of clinical psychopharmacology, 2001, Volume: 21, Issue:1

    Topics: Aged; Antipsychotic Agents; Benzodiazepines; Depression; Drug Interactions; Female; Fluoxetine; Haloperidol; Health Care Costs; Humans; Olanzapine; Parkinson Disease; Pirenzepine; Selegiline; Trihexyphenidyl

2001
3,4-methylenedioxymethamphetamine (MDMA, ecstasy)-mediated production of hydrogen peroxide in an in vitro model: the role of dopamine, the serotonin-reuptake transporter, and monoamine oxidase-B.
    Neuroscience letters, 2004, Aug-26, Volume: 367, Issue:1

    Topics: Cell Line, Tumor; Cell Survival; Choriocarcinoma; Dopamine; Drug Interactions; Female; Fluoxetine; Hallucinogens; Humans; Hydrogen Peroxide; Membrane Glycoproteins; Membrane Transport Proteins; Models, Biological; Monoamine Oxidase; Monoamine Oxidase Inhibitors; N-Methyl-3,4-methylenedioxyamphetamine; Nerve Tissue Proteins; Pregnancy; Selective Serotonin Reuptake Inhibitors; Selegiline; Serotonin Plasma Membrane Transport Proteins; Time Factors

2004
Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice.
    European journal of pharmacology, 2004, Sep-19, Volume: 499, Issue:1-2

    Topics: Animals; Antidepressive Agents; Clorgyline; Desipramine; Dose-Response Relationship, Drug; Fluoxetine; Hindlimb Suspension; Male; Mice; Morpholines; Motor Activity; Paroxetine; Pyrazoles; Pyrimidines; Pyrroles; Reboxetine; Receptors, Corticotropin-Releasing Hormone; Selegiline; Swimming; Tranylcypromine; Triazines

2004
Persistent sexual side effects after SSRI discontinuation.
    Psychotherapy and psychosomatics, 2006, Volume: 75, Issue:3

    Topics: Adult; Androgens; Anxiety; Bupropion; Cabergoline; Citalopram; Depressive Disorder; Dopamine Agonists; Dopamine Uptake Inhibitors; Ergolines; Female; Fluoxetine; Humans; Male; Monoamine Oxidase Inhibitors; Piperazines; Plants, Medicinal; Purines; Selective Serotonin Reuptake Inhibitors; Selegiline; Sertraline; Sexual Dysfunctions, Psychological; Sildenafil Citrate; Sleep Initiation and Maintenance Disorders; Sulfones; Testosterone; Time Factors; Treatment Outcome; Vasodilator Agents

2006
(-)-Trans-epsilon-viniferin, a polyphenol present in wines, is an inhibitor of noradrenaline and 5-hydroxytryptamine uptake and of monoamine oxidase activity.
    European journal of pharmacology, 2006, Aug-07, Volume: 542, Issue:1-3

    Topics: Animals; Benzofurans; Blood Platelets; Brain; Cell Line; Citalopram; Clorgyline; Dose-Response Relationship, Drug; Fluoxetine; Humans; Imipramine; Iproniazid; Isoenzymes; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Norepinephrine; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Selegiline; Serotonin; Stilbenes; Synaptosomes; Tritium; Wine

2006
Differential behavioral syndrome evoked in the rats after multiple doses of SSRI fluoxetine with selective MAO inhibitors rasagiline or selegiline.
    Journal of neural transmission (Vienna, Austria : 1996), 2008, Volume: 115, Issue:1

    Topics: Animals; Behavior, Animal; Brain; Drug Therapy, Combination; Fluoxetine; Indans; Male; Methamphetamine; Monoamine Oxidase Inhibitors; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Selegiline; Serotonin Syndrome

2008
Multiple medication use presenting as Parkinson's dementia complex: a message from Titanic.
    Journal of psychiatric practice, 2008, Volume: 14, Issue:1

    Topics: Aged; Anti-Infective Agents; Antiparkinson Agents; Antipsychotic Agents; Bacteriuria; Ciprofloxacin; Dementia; Drug Interactions; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Fluoxetine; Haloperidol; Hospitalization; Humans; Hypnotics and Sedatives; Lorazepam; Parkinson Disease; Psychomotor Agitation; Selegiline; Trihexyphenidyl

2008
Loss of schooling behavior in cavefish through sight-dependent and sight-independent mechanisms.
    Current biology : CB, 2013, Oct-07, Volume: 23, Issue:19

    Topics: Adaptation, Physiological; Animals; Behavior, Animal; Biological Evolution; Brain; Caves; Characidae; Dopamine; Fluoxetine; Lateral Line System; Lens, Crystalline; Monoamine Oxidase Inhibitors; Neurotransmitter Agents; Quantitative Trait Loci; Selection, Genetic; Selective Serotonin Reuptake Inhibitors; Selegiline; Serotonin; Vision, Ocular

2013
Inhibition of P-glycoprotein by psychotherapeutic drugs in a canine cell model.
    Journal of veterinary pharmacology and therapeutics, 2014, Volume: 37, Issue:5

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line; Clomipramine; Dogs; Fluoxetine; Gene Expression Regulation; Monoamine Oxidase Inhibitors; Selective Serotonin Reuptake Inhibitors; Selegiline

2014
Non-Serotonergic Neurotoxicity by MDMA (Ecstasy) in Neurons Derived from Mouse P19 Embryonal Carcinoma Cells.
    PloS one, 2016, Volume: 11, Issue:11

    Topics: Animals; Cell Differentiation; Cell Line, Tumor; Cell Survival; Clorgyline; Embryonal Carcinoma Stem Cells; Fluoxetine; Gene Expression; Membrane Potential, Mitochondrial; Mice; Monoamine Oxidase; N-Methyl-3,4-methylenedioxyamphetamine; Neurons; Selegiline; Serotonin Plasma Membrane Transport Proteins

2016
The role of nitric oxide-cGMP pathway in selegiline antidepressant-like effect in the mice forced swim test.
    Pharmacological reports : PR, 2018, Volume: 70, Issue:5

    Topics: Animals; Antidepressive Agents; Arginine; Cyclic GMP; Drug Synergism; Fluoxetine; Guanidines; Hippocampus; Immobility Response, Tonic; Indazoles; Male; Methylene Blue; Mice; Motor Activity; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitrites; Prefrontal Cortex; Selegiline; Signal Transduction; Sildenafil Citrate; Swimming

2018